Skip to main content

MESA LABORATORIES INC /CO/

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

MLAB$136.91+7.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

M****esa Laboratories, Inc.**

Condensed Consolidated Statements of Cash Flows

(in thousands)

Three Months Ended June 30,
20262025
Cash flows from operating activities:
Net income$2,830$4,742
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment1,2531,404
Amortization of intangible assets4,3924,553
Stock-based compensation expense2,3593,881
Foreign currency adjustments354(5,986)
Other6231,250
Cash from changes in operating assets and liabilities:
Accounts receivable, net9,7783,436
Inventories(1,533)(3,290)
Prepaid expenses and other assets(2,276)(2,436)
Accounts payable2,424212
Accrued liabilities and taxes payable(5,297)(5,928)
Unearned revenue(171)55
Net cash provided by operating activities14,7361,893
Cash flows from investing activities:
Purchases of property, plant and equipment(559)(1,009)
Net cash (used in) investing activities(559)(1,009)
Cash flows from financing activities:
Proceeds from debt borrowings10,00010,500
Debt repayments(18,656)(7,438)
GKE acquisition-related holdback payment-(9,555)
Dividends paid(884)(873)
Tax withholding on vesting of net restricted stock units(958)(1,061)
Net cash (used in) financing activities(10,498)(8,427)
Effect of exchange rate changes on cash and cash equivalents881,501
Net increase (decrease) in cash and cash equivalents3,767(6,042)
Cash and cash equivalents at beginning of period26,92827,321
Cash and cash equivalents at end of period$30,695$21,279
Supplemental non-cash activity:
Right of use assets obtained in exchange for lease liabilities$1,062$511

See accompanying notes to Condensed Consolidated Financial Statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.